Life Sciences' Next Generation AI Market Revenues and Trends 2025-2033
Global next-generation AI in Life Sciences Market is transforming your creations using advanced AI solutions that promote advanced AI solutions globally. This market is growing as life sciences organizations apply advanced artificial intelligence, especially generative artificial intelligence, ML, and cloud computing to accelerate drug discovery, optimize clinical trials, enhance diagnosis, and provide personalized healthcare, providing all the time, costs and risks of R&D.
What is the next generation AI in life sciences?
Life Sciences' Next Generation AI refers to advanced artificial intelligence technologies that enable a more accurate, efficient and predictive approach to drug discovery, diagnosis, personalized medicine, and clinical decision-making. AI agents with natural language interfaces make computational tools and datasets more accessible, enabling researchers of all skill levels to use these resources to accelerate their work. A few key factors are driving the growth of next-generation AI in the life sciences market. With the explosion of genome, proteome, imaging, and OMICS datasets, AI analysis must efficiently manage vast, complex and diverse biological data.
Pharmaceutical and biotechnology companies are increasingly turning their eyes to AI-powered tools for virtual screening, molecular design and safety predictions to reduce timelines and costs associated with drug development. Supporting regulations and funding encourage technology companies, academic institutions, and drug developers to adopt AI-enabled platforms. Advances in computing power and algorithm development have made sophisticated AI applications more deployable and practical.
Segment Insights:
- Depending on the application areaDiscovery and Development segment dominated the market in 2024. This is primarily due to the ability of AI to significantly accelerate target identification, molecular screening and predictive modeling, reducing both time and cost.
- Depending on the technology typeMachine Learning is the dominant segment in the market due to its adaptability across a variety of life science applications and the ability to continuously improve results with additional data.
- By end users, The Pharmaceutical & Biotechnology Companies segment led the market in 2024 with its high investment in AI platforms to reduce R&D time, improve success rates when tracking R&D efforts, and manage regulatory challenges.
- Depending on the deployment modethe cloud-based segment dominated this market in 2024. The cloud platform makes it easier to collaborate in real time, faster data processing, and integrate AI tools, making it a favourable option for Pharma, Biotech and research institutions looking for cost-effective agile AI deployments.
Local insights:
North America registered its dominance in the next generation AI in the life sciences market, which holds its largest share in 2024. This is primarily due to its robust life science ecosystem, substantial R&D investment, a lucrative regulatory environment for AI, and the involvement of key technology companies in both AI and life sciences. Additionally, collaborations between high-tech companies and life sciences organizations have further accelerated the adoption of AI across drug discovery, diagnostics and clinical trials in the region.
The Asia-Pacific region is projected to experience rapid growth during the forecast period. This growth is driven by increased government funding for R&D, expansion of the biotech sector, improved cloud and AI infrastructure, and increased demand for precision diagnosis and affordable treatments. Government initiatives to support the growing digital health, R&D activities and the need for cost-effective and scalable AI solutions in drug development will further drive regional market growth.
Next-Generation AI in Life Sciences Market Coverage
| Report attributes | Important statistics |
| Quantitative Unit | Revenues of USD 1 million/USD 1 billion, unit volume |
| The largest market | North America |
| Base year | 2024 |
| Covered areas | North America, Europe, Asia Pacific, Latin America, Middle East & Africa |
Recent developments:
- September 9, 2025, Eli Lily and the company have launched Lilly Tunelab, an AI/ML platform. The platform provides access to biotech companies to drug discovery models trained with Lily's long-standing research data.
(source- https://investor.lilly.com)
Get this report to explore the size, share, CAGR and trends of the global market. Detailed segment analysis and insightful competitive landscape overview @ https://www.precedenceresearch.com/sample/6857
You can also place an order or ask a question. sales@precedenceresearch.com | +1 804 441 9344
